Literature DB >> 9796987

Search for the optimal schedule for the oxaliplatin/5-fluorouracil association modulated or not by folinic acid: preclinical data.

J L Fischel1, M C Etienne, P Formento, G Milano.   

Abstract

The combination of oxaliplatin (LOHP)-5-fluorouracil (FU)-folinic acid (FA) has provided high response rates in pretreated patients with advanced colorectal cancer that is resistant to FU-FA. However, the choice of the optimal schedule between LOHP, FU, and FA remains open. The purpose of the present study was to compare, at equivalent drug area under the curve, different schedules for the LOHP-FU +/- FA combinations on four human colorectal cancer cell lines. FU +/- FA was tested as a 2-h short exposure ("bolus"), a 118-h continuous exposure ("infusion"), or a 22-h mixed exposure ("De Gramont protocol"). LOHP was administered for 2 h before, during, or after FU +/- FA exposure. Isobologram analyses revealed that LOHP associated with FU +/- FA resulted in synergistic cytotoxic effects whatever the tested schedules (in > or = 75% of cases). For the FU-LOHP combination, cytotoxicity was significantly different according to the FU exposure type (short > mixed > continuous) and was independent of the LOHP position. In contrast, for the FU-FA-LOHP combination, neither the FU exposure type nor the LOHP position significantly influenced cytotoxicity. The presence of FA significantly enhanced the cytotoxicity of FU-LOHP (P < 0.001); this potentiation was independent of the FU exposure type and was significantly influenced by the LOHP position (LOHP after FU-FA > LOHP during FU-FA > LOHP before FU-FA). In conclusion, in contrast with the recognized superiority of continuous FU exposure over short exposure when the drug is given alone, the FU-LOHP combination is more cytotoxic when FU is given as a short exposure. This suggests the potential interest of such a schedule in the clinical setting.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9796987

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  16 in total

Review 1.  Oxaliplatin: in operable colorectal cancer.

Authors:  Susan J Keam; Christopher J Dunn; David P Figgitt
Journal:  Drugs       Date:  2005       Impact factor: 9.546

Review 2.  Chemo-immunotherapy of colorectal carcinoma: preclinical rationale and clinical experience.

Authors:  Pierpaolo Correale; Maria Grazia Cusi; Lucia Micheli; Cristina Nencini; Maria Teresa Del Vecchio; Francesco Torino; Angelo Aquino; Enzo Bonmassar; Guido Francini; Giorgio Giorgi
Journal:  Invest New Drugs       Date:  2006-03       Impact factor: 3.850

Review 3.  Oxaliplatin: pharmacokinetics and chronopharmacological aspects.

Authors:  F Lévi; G Metzger; C Massari; G Milano
Journal:  Clin Pharmacokinet       Date:  2000-01       Impact factor: 6.447

Review 4.  Oxaliplatin. A review of its pharmacological properties and clinical efficacy in metastatic colorectal cancer and its potential in other malignancies.

Authors:  C R Culy; D Clemett; L R Wiseman
Journal:  Drugs       Date:  2000-10       Impact factor: 9.546

Review 5.  Toxicity patterns of cytotoxic drugs.

Authors:  Etienne Chatelut; Jean-Pierre Delord; Pierre Canal
Journal:  Invest New Drugs       Date:  2003-05       Impact factor: 3.850

6.  Phase I study of oxaliplatin in combination with gemcitabine, irinotecan, and 5-fluorouracil/leucovorin (G-FLIE) in patients with metastatic solid tumors including adenocarcinoma of the pancreas.

Authors:  Adam J Olszewski; Michael L Grossbard; Michael S Chung; Sree B Chalasani; Stephen Malamud; Tahir Mirzoyev; Peter S Kozuch
Journal:  J Gastrointest Cancer       Date:  2013-06

Review 7.  Oxaliplatin: a review of its use in combination therapy for advanced metastatic colorectal cancer.

Authors:  Dene Simpson; Christopher Dunn; Monique Curran; Karen L Goa
Journal:  Drugs       Date:  2003       Impact factor: 9.546

8.  Randomised trial comparing biweekly oxaliplatin plus oral capecitabine versus oxaliplatin plus i.v. bolus fluorouracil/leucovorin in metastatic colorectal cancer patients: results of the Southern Italy Cooperative Oncology study 0401.

Authors:  Pasquale Comella; Bruno Massidda; Gianfranco Filippelli; Antonio Farris; Donato Natale; Giuseppe Barberis; Luigi Maiorino; Sergio Palmeri; Michele Cannone; Giovanni Condemi
Journal:  J Cancer Res Clin Oncol       Date:  2008-08-22       Impact factor: 4.553

9.  Oxaliplatin and Bolus-Modulated 5-Fluorouracil as a Second-Line Treatment for Advanced Pancreatic Cancer: Can Bolus Regimens Replace FOLFOX When Considered for Second Line?

Authors:  A Azmy; S Abdelwahab; M Yassen
Journal:  ISRN Oncol       Date:  2013-02-24

10.  Phase II study of a triplet regimen in advanced colorectal cancer using methotrexate, oxaliplatin and 5-fluorouracil.

Authors:  A Guglielmi; S Barni; A Zaniboni; N Pella; O Belvedere; G D Beretta; F Grossi; L Frontini; F Puglisi; R Labianca; A Sobrero
Journal:  Br J Cancer       Date:  2004-10-18       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.